Truffle Capital

Wyden is a leading provider of institutional digital asset trading technology, designed to meet the needs of financial institutions. The company's platform encompasses the entire trade lifecycle, from pre-trade risk assessments to order generation, automated settlement, and integration with custody, core banking, and portfolio management systems. This comprehensive approach enables clients to seamlessly navigate the complexities of trading both digital and traditional assets. Developed by a team of experienced professionals in trading systems and crypto assets, Wyden's infrastructure solutions are tailored for institutional requirements. The company operates offices in Zurich, New York, and Singapore, reflecting its global presence in the financial technology sector.

DgPays is a financial technology company that specializes in providing comprehensive payment solutions tailored for banks, e-money institutions, telecom operators, and transportation operators. The company's platform includes a range of services such as online and mobile payment systems, mobile wallets, prepaid cards, and bill payment solutions. Additionally, DgPays offers tools for managing loyalty programs and payment gateway infrastructure. Their solutions also encompass essential banking services, including compliance, fraud management, and authentication, ensuring secure and efficient financial transactions. By integrating these diverse services, DgPays aims to facilitate seamless and convenient financial experiences for its clients and their customers.

Obat is a developer of invoicing and payment software tailored for small and medium enterprises in the construction industry. The company provides a platform that includes features for estimation, project management, site monitoring, and invoicing specifically for building craftsmen. By continually adapting its software based on feedback from customers and partners, Obat aims to help contractors and independent contractors enhance their operational efficiency and maximize their value proposition.

Levenue is a European revenue-based financing platform aimed at helping founders unlock the value of their recurring revenues. The company has developed a marketplace that connects institutional investors with businesses seeking growth capital. By transforming recurring revenues into upfront cash, Levenue enables companies to obtain funding quickly without diluting shareholder equity or relying on significant consumer discounts. The platform not only facilitates funding requests but also offers insights into business metrics, allowing clients to finance their growth while maintaining control over their operations. Levenue's mission is to empower founders to focus on their core business objectives.

MoneyTrack is a global decentralized blockchain platform designed to facilitate structured financial exchanges between financiers, beneficiaries, and partners. The company develops a payment platform that allows users to establish directed money programs with customizable features, pricing, and commission structures. This innovative approach enables end-users to access markets more easily while reducing operational costs. Through its technology, MoneyTrack aims to streamline financial transactions and improve efficiency within the financial ecosystem.

Obat is a developer of invoicing and payment software tailored for small and medium enterprises in the construction industry. The company provides a platform that includes features for estimation, project management, site monitoring, and invoicing specifically for building craftsmen. By continually adapting its software based on feedback from customers and partners, Obat aims to help contractors and independent contractors enhance their operational efficiency and maximize their value proposition.

Abivax is a clinical-stage biotechnology company based in France, dedicated to developing innovative therapeutics that leverage the body's natural immune mechanisms to treat patients with autoimmune diseases, viral infections, and cancer. The company's primary focus is on chronic inflammatory diseases, particularly inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. Abivax is currently evaluating its leading drug candidate, obefazimod, in Phase 3 clinical trials aimed at addressing moderately to severely active ulcerative colitis. Through its drug development platforms, Abivax strives to deliver novel and effective treatments to patients with significant unmet medical needs in these therapeutic areas.

Bridge is a banking data and payment system. They offer banking aggregation, payment initiation, open data, electronic invoices, debt collection, e-commerce sites and digital and physical commerce, factoring, kitty service, wallets, single and multiple payments, finance and insurance, credit, risk, and fraud experts.

Cachet OÜ, established in 2018 and headquartered in Tallinn, Estonia, operates an innovative online insurance brokerage platform focused on the mobility sector, particularly for ride-hailing drivers. The company offers a variety of insurance products, including traffic and casco insurance, as well as fleet insurance. Cachet serves as a data intermediary between gig economy platforms and insurance providers by aggregating and enriching data on service provision across multiple platforms. This data-driven approach enables insurance companies to deliver personalized coverage options tailored to individual service providers based on their actual working hours, thereby enhancing pricing, predictability, and risk management within the gig and sharing economy.

RollingFunds is a financial technology company founded in 2018 and based in Paris, France. It specializes in providing short-term financing solutions to small and medium enterprises through its innovative credit management platform. The platform employs machine learning-based instant scoring algorithms to automate the loan granting and management process, making it easier for businesses to access the cash they need. By facilitating financing in B2B relationships, RollingFunds enhances the integration of financial solutions into the operational environment of its clients, enabling them to offer tailored financing options to their partners.

Cake App mission is to become the leading software technology provider that analyzes financial data to help people better understand, control and improve their finances, supported by a business model that shares our revenue with users.

IPaidThat is a financial technology company that offers a platform aimed at simplifying and automating accounting processes for startups and small to medium-sized enterprises (SMEs). The platform utilizes artificial intelligence to automatically import and manage financial documents, including expense reports and supplier invoices. By comparing these documents with bank transactions, IPaidThat ensures that users do not overlook any financial details, thereby streamlining their accounting practices. This solution is designed to enhance efficiency and accuracy in financial management for businesses, allowing them to focus on growth rather than administrative tasks.

Monisnap SAS is a French fintech company based in Paris, founded in 2017. It operates a digital instant money transfer platform and mobile application designed to facilitate the sending of money abroad. The platform allows users to transfer funds quickly and efficiently to family, friends, and business partners from Europe to various destinations worldwide. Monisnap aims to enhance the remittance experience by offering a seamless and user-friendly service.

Zaion is a European company that specializes in customer relationship solutions powered by artificial intelligence. It has developed an AI-driven conversational platform that automates interactions and enhances customer engagement through voice processing. The platform enables businesses to streamline their communication by utilizing remote advisors to handle customer inquiries, resulting in more personalized interactions and quicker response times. This innovative approach aims to improve overall customer satisfaction while simultaneously reducing operational costs for businesses.

Acasi SAS is a company based in Paris, France, that specializes in developing accounting management software tailored for freelancers across various sectors, including architecture, law, consultancy, and coaching. Founded in 2017, Acasi's software streamlines financial management by automating tasks such as online quotations, invoicing, VAT management, and expense tracking. Additionally, it provides real-time cash monitoring and personalized financial coaching, helping users alleviate the administrative burdens associated with their accounting practices. Through its innovative solutions, Acasi aims to enhance the efficiency and effectiveness of financial management for freelancers.

MoneyTrack is a global decentralized blockchain platform designed to facilitate structured financial exchanges between financiers, beneficiaries, and partners. The company develops a payment platform that allows users to establish directed money programs with customizable features, pricing, and commission structures. This innovative approach enables end-users to access markets more easily while reducing operational costs. Through its technology, MoneyTrack aims to streamline financial transactions and improve efficiency within the financial ecosystem.

Smile & Pay is a company that specializes in electronic payment solutions, providing small and medium-sized merchants with innovative tools to accept payments via smartphones. Its product lineup includes PocketSmile, a compact mobile terminal that accommodates all credit cards, and MaxiSmile, which features both a printer and mobile GPRS capabilities. In addition to facilitating card payments, Smile & Pay offers software that allows users to track and manage transactions and accounts online, enabling efficient payment processing in various settings without the need for traditional payment terminals. By focusing on user-friendly technology, Smile & Pay enhances the payment experience for both merchants and customers.

Particeep is a fintech company that specializes in providing banks, insurers, asset managers, and their distributors with efficient, no-code solutions for the online distribution of financial products and services. The company offers a platform that allows these institutions to establish digital subscription channels quickly—typically within a month—without the need for any IT development. Particeep's services include a REST API composed of micro-services tailored for banking, insurance, and investment sectors, facilitating seamless data sharing with various information systems and third-party applications. This innovative approach enables financial institutions to enhance their digital capabilities and streamline their product offerings effectively.

WeGroup is a Belgian InsurTech company that assists insurance brokers in better engaging with their digitally expanding client base through "Louise," its 24/7 virtual assistant powered by data analytics and robotic automation. This innovative approach has earned WeGroup over 15 international awards, serving clients such as insurance companies, intermediaries, and banks across Europe. By employing Louise, these clients can focus more on their customers while benefiting from faster, better, and more personalized service.

Monisnap SAS is a French fintech company based in Paris, founded in 2017. It operates a digital instant money transfer platform and mobile application designed to facilitate the sending of money abroad. The platform allows users to transfer funds quickly and efficiently to family, friends, and business partners from Europe to various destinations worldwide. Monisnap aims to enhance the remittance experience by offering a seamless and user-friendly service.

RollingFunds is a financial technology company founded in 2018 and based in Paris, France. It specializes in providing short-term financing solutions to small and medium enterprises through its innovative credit management platform. The platform employs machine learning-based instant scoring algorithms to automate the loan granting and management process, making it easier for businesses to access the cash they need. By facilitating financing in B2B relationships, RollingFunds enhances the integration of financial solutions into the operational environment of its clients, enabling them to offer tailored financing options to their partners.

IPaidThat is a financial technology company that offers a platform aimed at simplifying and automating accounting processes for startups and small to medium-sized enterprises (SMEs). The platform utilizes artificial intelligence to automatically import and manage financial documents, including expense reports and supplier invoices. By comparing these documents with bank transactions, IPaidThat ensures that users do not overlook any financial details, thereby streamlining their accounting practices. This solution is designed to enhance efficiency and accuracy in financial management for businesses, allowing them to focus on growth rather than administrative tasks.

Smile & Pay is a company that specializes in electronic payment solutions, providing small and medium-sized merchants with innovative tools to accept payments via smartphones. Its product lineup includes PocketSmile, a compact mobile terminal that accommodates all credit cards, and MaxiSmile, which features both a printer and mobile GPRS capabilities. In addition to facilitating card payments, Smile & Pay offers software that allows users to track and manage transactions and accounts online, enabling efficient payment processing in various settings without the need for traditional payment terminals. By focusing on user-friendly technology, Smile & Pay enhances the payment experience for both merchants and customers.

MoneyTrack is a global decentralized blockchain platform designed to facilitate structured financial exchanges between financiers, beneficiaries, and partners. The company develops a payment platform that allows users to establish directed money programs with customizable features, pricing, and commission structures. This innovative approach enables end-users to access markets more easily while reducing operational costs. Through its technology, MoneyTrack aims to streamline financial transactions and improve efficiency within the financial ecosystem.

Géocorail développe et commercialise un produit innovant faisant travailler la mer à la protection du littoral : le Géocorail®. Ce procédé électrochimique breveté innovant consiste à créer une roche artificielle permettant de protéger les ouvrages marins et de lutter contre l’érosion du littoral.

Theraclion is a French company founded in 2004, specializing in high-tech medical equipment that utilizes high-intensity focused ultrasound (HIFU) for therapeutic purposes. It develops, manufactures, and markets innovative medical devices, notably the Echopulse®, designed for the non-invasive treatment of breast fibroadenomas and benign thyroid nodules. Additionally, the company offers the SONOVEIN®, which is aimed at treating varicose veins in the lower limbs. Theraclion’s echotherapy solutions integrate HIFU with ultrasound technology, enabling precise localization of target areas for effective treatment of benign tumors and varicose veins.

Myopowers Medical Technologies is a French medical device company that develops innovative technologies to provide muscle assistance to patients with high unmet medical needs. The technology can be applied to a number of indications in the GI, cardiology or urology area. The company focus is the development of ARTUS, a new and unique implantable device for the treatment of stress urinary incontinence. Stress urinary incontinence is a condition that affects millions of people around the world. Unfortunately, currently available products are old with significant limitations such as tissue erosion, infection or mechanical failure leading frequent re-operation. ARTUS is made of smooth and flat silicon cuff placed around the urethra. It is individually actionable and adjustable with a remote control allowing patients easy voiding and the surgeon monitoring and adjusting the cuff. This device is the first artificial urinary system specifically designed to include the treatment of female patients who account for a vast majority of the urinary incontinence market.

Actility S.A., founded in 2010 and headquartered in Lannion, France, is a leader in Low Power Wide Area Networks (LPWAN) and specializes in machine-to-machine communication solutions. The company's flagship platform, ThingPark, provides a carrier-grade Internet of Things (IoT) infrastructure that supports scalable deployments of mission-critical applications. ThingPark facilitates the connection between sensors and cloud applications, accommodating a wide range of use cases from global networks to secure enterprise solutions. Actility features a growing ecosystem of partners and offers middleware that enables seamless integration of data from various sensors. Additionally, the company operates a B2B e-commerce marketplace that connects businesses with vetted IoT device, connectivity, and application providers. As a founding member of the LoRa Alliance™, Actility is committed to advancing IoT technologies and fostering collaboration within the industry.

Altimmune, Inc. is a clinical stage biopharmaceutical company based in Gaithersburg, Maryland, specializing in the development of innovative treatments for liver disease, obesity, and vaccines. The company’s pipeline includes HepTcell, an immunotherapeutic candidate for chronic hepatitis B, which has successfully completed Phase I clinical trials. Altimmune also develops NasoShield, an intranasal anthrax vaccine, and NasoVAX, a recombinant intranasal vaccine. Additionally, the company is advancing AdCOVID, a single-dose intranasal vaccine for COVID-19. In the preclinical stage, Altimmune is working on ALT-801, a peptide-based dual GLP-1/glucagon receptor agonist for non-alcoholic steatohepatitis, as well as ALT-702, a tumor immunostimulant aimed at cancer treatment. The company employs proprietary technology for non-invasive intranasal delivery of its products and collaborates with institutions such as the University of Alabama at Birmingham to further its research initiatives.

SP3H is a company focused on developing innovative technology to address environmental challenges, particularly in reducing carbon dioxide emissions and fuel consumption. The company specializes in smart optical sensor technology that aims to control pollutant emissions in industrial settings. By utilizing near-infrared systems, SP3H's sensors analyze the molecular structure of liquid fuels in vehicles and adjust operational settings based on the quality of the fuel detected. This capability enhances combustion efficiencies, allowing clients to optimize fuel use and minimize their environmental impact. Overall, SP3H is dedicated to advancing sustainable practices through its cutting-edge technological solutions.

CoolGames is a developer of cloud-based interactive and casual games, focusing on delivering high-quality gaming experiences to players worldwide. Since its establishment in 2009, the company has utilized 100% HTML5 technology to publish a diverse portfolio of games, including well-known intellectual properties such as Angry Birds, Tetris, Snake, and Battleship. By offering a click-and-play platform, CoolGames allows users to access and enjoy its games on various devices, including smartphones, personal computers, and tablets, without the need for downloads. This approach ensures that players can engage with their favorite games anytime and anywhere, reflecting the company's commitment to providing accessible and enjoyable gaming experiences.

MoMac is a global technology company specializing in customer engagement solutions for leading Communication Service Providers (CSPs). It operates the mvolve platform, which integrates internal data systems, service offerings, content, and on-device user interfaces to enhance CSP-customer interactions. This integration enables CSPs to reduce costs, increase revenue, and accelerate solution deployment. MoMac serves prominent CSP clients such as Orange Group, Vodafone, Telefónica, Three, KPN, and T-Mobile across 27 countries, with offices in the US, UK, Netherlands, and France.

Carbios is a company focused on developing innovative enzymatic bioprocesses for recycling plastic and textile polymers. It specializes in creating biodegradable plastics through a method that enables the recycling of plastic waste, particularly polyethylene terephthalate (PET), which is commonly found in bottles and containers. By utilizing enzymes to decompose and recycle PET, Carbios aims to promote a circular economy and mitigate the environmental issues associated with plastic pollution. The company is committed to advancing sustainable technologies, offering a new generation of fully biodegradable plastics with controlled lifespans and infinite recycling capabilities. Through its biorecycling and bioproduction techniques, Carbios seeks to contribute to a more sustainable future by addressing the challenges posed by plastic waste.

SP3H is a company focused on developing innovative technology to address environmental challenges, particularly in reducing carbon dioxide emissions and fuel consumption. The company specializes in smart optical sensor technology that aims to control pollutant emissions in industrial settings. By utilizing near-infrared systems, SP3H's sensors analyze the molecular structure of liquid fuels in vehicles and adjust operational settings based on the quality of the fuel detected. This capability enhances combustion efficiencies, allowing clients to optimize fuel use and minimize their environmental impact. Overall, SP3H is dedicated to advancing sustainable practices through its cutting-edge technological solutions.

Pharnext SA is a clinical-stage biopharmaceutical company based in Issy-Les-Moulineaux, France, founded in 2007 by leading scientists in genomics. The company focuses on developing innovative therapies for both orphan and common neurodegenerative diseases, where treatment options are currently limited. Its notable products include SYNGILITY, which has successfully completed Phase III trials for Charcot-Marie-Tooth disease type 1A, and PXT864, which has shown promise in Phase II trials for Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Pharnext employs its proprietary PLEOTHERAPY platform, which utilizes network pharmacology and extensive genomic data to identify synergistic combinations of existing approved drugs, termed PLEODRUGs. This approach aims to optimize drug efficacy and safety while securing intellectual property through granted patents. Additionally, Pharnext has collaborated with the University Hospital Institute Mediterranee Infection to explore repurposed drugs for potential COVID-19 applications.

CoolGames is a developer of cloud-based interactive and casual games, focusing on delivering high-quality gaming experiences to players worldwide. Since its establishment in 2009, the company has utilized 100% HTML5 technology to publish a diverse portfolio of games, including well-known intellectual properties such as Angry Birds, Tetris, Snake, and Battleship. By offering a click-and-play platform, CoolGames allows users to access and enjoy its games on various devices, including smartphones, personal computers, and tablets, without the need for downloads. This approach ensures that players can engage with their favorite games anytime and anywhere, reflecting the company's commitment to providing accessible and enjoyable gaming experiences.

Biokinesis is a biotechnology company developing new treatments for cancer by targeting a specific kinesin found in several cancers.

Pharnext SA is a clinical-stage biopharmaceutical company based in Issy-Les-Moulineaux, France, founded in 2007 by leading scientists in genomics. The company focuses on developing innovative therapies for both orphan and common neurodegenerative diseases, where treatment options are currently limited. Its notable products include SYNGILITY, which has successfully completed Phase III trials for Charcot-Marie-Tooth disease type 1A, and PXT864, which has shown promise in Phase II trials for Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Pharnext employs its proprietary PLEOTHERAPY platform, which utilizes network pharmacology and extensive genomic data to identify synergistic combinations of existing approved drugs, termed PLEODRUGs. This approach aims to optimize drug efficacy and safety while securing intellectual property through granted patents. Additionally, Pharnext has collaborated with the University Hospital Institute Mediterranee Infection to explore repurposed drugs for potential COVID-19 applications.

Myopowers Medical Technologies is a French medical device company that develops innovative technologies to provide muscle assistance to patients with high unmet medical needs. The technology can be applied to a number of indications in the GI, cardiology or urology area. The company focus is the development of ARTUS, a new and unique implantable device for the treatment of stress urinary incontinence. Stress urinary incontinence is a condition that affects millions of people around the world. Unfortunately, currently available products are old with significant limitations such as tissue erosion, infection or mechanical failure leading frequent re-operation. ARTUS is made of smooth and flat silicon cuff placed around the urethra. It is individually actionable and adjustable with a remote control allowing patients easy voiding and the surgeon monitoring and adjusting the cuff. This device is the first artificial urinary system specifically designed to include the treatment of female patients who account for a vast majority of the urinary incontinence market.

Utel SAS, based in Paris, France, specializes in creating mobile applications for social networking and collaborative services. The company's flagship platform, Allokang, enables users to buy or sell skills, talents, and expertise across various fields, including legal, financial, academic support, IT, mental health, personal development, entertainment, and astrology. Additionally, Utel offers Backstage SMS, which provides tools for interactive engagement such as game initiation and voting, alongside a web interface that allows animators to manage listener messages and multimedia submissions. This functionality also enables monetization of community page traffic, allowing users to participate in paid activities. Established in 2000, Utel continues to innovate in the mobile application space.

Actility S.A., founded in 2010 and headquartered in Lannion, France, is a leader in Low Power Wide Area Networks (LPWAN) and specializes in machine-to-machine communication solutions. The company's flagship platform, ThingPark, provides a carrier-grade Internet of Things (IoT) infrastructure that supports scalable deployments of mission-critical applications. ThingPark facilitates the connection between sensors and cloud applications, accommodating a wide range of use cases from global networks to secure enterprise solutions. Actility features a growing ecosystem of partners and offers middleware that enables seamless integration of data from various sensors. Additionally, the company operates a B2B e-commerce marketplace that connects businesses with vetted IoT device, connectivity, and application providers. As a founding member of the LoRa Alliance™, Actility is committed to advancing IoT technologies and fostering collaboration within the industry.

Pharnext SA is a clinical-stage biopharmaceutical company based in Issy-Les-Moulineaux, France, founded in 2007 by leading scientists in genomics. The company focuses on developing innovative therapies for both orphan and common neurodegenerative diseases, where treatment options are currently limited. Its notable products include SYNGILITY, which has successfully completed Phase III trials for Charcot-Marie-Tooth disease type 1A, and PXT864, which has shown promise in Phase II trials for Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Pharnext employs its proprietary PLEOTHERAPY platform, which utilizes network pharmacology and extensive genomic data to identify synergistic combinations of existing approved drugs, termed PLEODRUGs. This approach aims to optimize drug efficacy and safety while securing intellectual property through granted patents. Additionally, Pharnext has collaborated with the University Hospital Institute Mediterranee Infection to explore repurposed drugs for potential COVID-19 applications.

Immune Targeting Systems Limited is a biotechnology company focused on developing synthetic vaccines for mutating viruses. Based in London at the London BioScience Innovation Centre, the company was founded in late 2003. Its core technology involves targeting highly conserved parts of viruses to direct a T-cell immune response against infected cells. The company's fluoropeptide vaccine technology delivers these antigens into the body, promoting robust T-cell immunity without needing potentially toxic adjuvants typically used to boost vaccine responses. ITS is developing FP-01, a synthetic vaccine effective against various seasonal and pandemic influenza strains, as well as vaccines for life-threatening viral infections such as HIV/AIDS, hepatitis, and FIV (cat AIDS).

Symetis is a Swiss company based in Ecublens that specializes in developing innovative minimally invasive heart valve replacement therapies. The company focuses on improving patient care and safety through its proprietary Acurate™ Aortic Valve Replacement System, which features a unique self-positioning design. This design allows for easier implant positioning and alignment, enhancing the overall user experience for healthcare providers. Symetis aims to address the needs of patients suffering from aortic valve stenosis, enabling the effective treatment of severe cardiac valve conditions through its advanced transcatheter aortic valve implantation devices.

Eco-Carbone provides consulting and project development services in the area of climate change mitigation.

Carmat is a French medtech company that specializes in the development and manufacturing of bioprosthetic artificial hearts. Founded in 2008 and headquartered in Vélizy-Villacoublay, the company creates biocompatible, auto-regulated total artificial hearts designed to closely mimic the human heart's structure, including both right and left ventricles. These devices are intended for patients suffering from chronic terminal heart failure classified as class IV by the New York Heart Association, as well as those experiencing acute terminal heart failure due to massive myocardial infarction. Carmat aims to provide a reliable and innovative therapeutic solution for heart failure patients who are ineligible for transplants and have exhausted other treatment options. In addition to the artificial hearts, the company develops the necessary power supply systems and remote diagnostic systems for these devices.

OSEAD Maroc Mining operates as a metal and mining platform. OSEAD is a holding company specialising in the prospecting, exploration and mining of mineral deposits. OSEAD’s main asset is Compagnie Minière de Touissit the second largest private mining operator in Morocco, which mines primarily lead and silver with some zinc.

PeopleCube is a provider of intelligent on-demand workplace management solutions headquartered in Framingham, Massachusetts, with additional offices worldwide. The company offers a suite of software designed for scheduling and facility management, enabling organizations to optimize their workspace usage and reduce costs associated with real estate, meeting services, travel, and energy. Among its offerings are resource scheduling software, which facilitates the management of alternative workspaces, room bookings, video conferencing, and visitor and event management. With a customer base of approximately 7,500 organizations across various sectors, PeopleCube aims to enhance operational efficiency through its data-driven approach to workplace management.

Neovacs is a biotechnology company founded in 1993 as a spin-off from the Pierre & Marie Curie University in Paris by Professor Daniel Zagury, a prominent immunologist. The company specializes in the development of therapeutic vaccines known as "Kinoids," which are designed to treat a range of conditions including autoimmune diseases, allergies, and cancer. Neovacs holds an extensive patent portfolio and is recognized for its innovative approach to vaccine development, particularly in creating vaccines that target human cytokines and immunosuppressive viral proteins. Unlike traditional monoclonal antibody treatments that provide exogenous therapies, Neovacs' therapeutic vaccines promote a robust natural polyclonal antibody response in patients, positioning the company as a pioneer in the field of immunotherapy.

Immune Targeting Systems Limited is a biotechnology company focused on developing synthetic vaccines for mutating viruses. Based in London at the London BioScience Innovation Centre, the company was founded in late 2003. Its core technology involves targeting highly conserved parts of viruses to direct a T-cell immune response against infected cells. The company's fluoropeptide vaccine technology delivers these antigens into the body, promoting robust T-cell immunity without needing potentially toxic adjuvants typically used to boost vaccine responses. ITS is developing FP-01, a synthetic vaccine effective against various seasonal and pandemic influenza strains, as well as vaccines for life-threatening viral infections such as HIV/AIDS, hepatitis, and FIV (cat AIDS).

Cytomics Systems is a French private company that offers bio-pharmacology services. The company uses Yeast Micro-Lab technology, a protenomics tool, which enables to follow in-vitro deterioration of proteins. Cytomics Systems's research and development focuses on fungicidal infections, inflammatory illnesses, and cancers. Cytomics Systems, S.A was founded in 2000 and is based in Gif-sur-Yvette, France.

RF-iT Solutions GmbH specializes in radio frequency identification (RFID) software solutions and services, established in 2005 and headquartered in Graz, Austria, with additional locations in Germany, France, and the United Kingdom. The company develops and markets a range of products, including the You-R® OPEN platform, designed for system integrators and software manufacturers, and a variety of RFID infrastructure tools such as smart labels, readers, barcode scanners, and label printers. Its software offerings include You-R Smart Fashion for textile supply chains, You-R® DOCUTRACER for data management in legal and healthcare sectors, You-R® PHARMA for pharmaceutical packaging, You-R® RETAIL for inventory management, You-R® SECURE for brand protection, and You-R® VIRTUAL TUNNEL for unit allocation in packaging. Alongside its products, RF-iT Solutions provides consulting services, feasibility studies, and testing to various industries, including fashion, automotive, pharmaceuticals, retail, and healthcare.

Deinove SA is a biotechnology company based in Grabels, France, focused on discovering, developing, and producing microbial-derived compounds for the health, nutrition, and cosmetics sectors. The company is advancing its portfolio of antibiotic candidates, including DNV3837, which is currently undergoing Phase II clinical trials for treating Clostridioides difficile infections. In the cosmetics arena, Deinove offers various bioactive ingredients such as PHYT-N-Resist, Luminity, HEBELYS, and BIOME Oléoactif, which serve functions ranging from anti-aging to balancing skin microbiota. Additionally, Deinove is exploring processes for producing natural ingredients for animal feed. The company has established partnerships with several organizations, including bioMérieux and the Institut Pasteur, to enhance its research and development initiatives. Founded in 2006, Deinove is committed to leveraging its bacterial biodiversity to create sustainable solutions across multiple industries.

TheraDiag is a France-based company specializing in the development, manufacturing, and marketing of in-vitro diagnostic products. Founded in 1986 and headquartered in Marne La Vallée, the company offers a range of diagnostic tools, including reagents for autoimmune and infectious diseases, as well as fertility tests. Notable products include IMMUNO-TROL, a quality control tool; various instruments for disease testing; and the SQA-V semen analyzer. TheraDiag also provides advanced instrumentation such as the Theralis platform, which integrates immunofluorescence and ELISA technologies, and the FIDIS platform for laboratory analysis. Additionally, the company offers therapeutic drug monitoring services for chronic inflammatory diseases and LISA tracker, a tool designed for monitoring biotherapies.

AS Group is a Parisian company and a spin-off of Deloitte, was a corporate performance software vendor.

EquiTime is a provider of workforce management solutions designed to assist organizations in effectively managing employee schedules while accommodating the unique requirements of various professions. The company innovates traditional time and activity management by incorporating forecasting capabilities alongside actual work performance, thereby enhancing productivity and fostering better relationships between employees and customers. EquiTime's core product, AgileTime, is complemented by a range of services including training, integration with human resource information systems (HRIS), tailored developments, and functional support, ensuring clients can fully leverage the benefits of their workforce management systems.

TheraDiag is a France-based company specializing in the development, manufacturing, and marketing of in-vitro diagnostic products. Founded in 1986 and headquartered in Marne La Vallée, the company offers a range of diagnostic tools, including reagents for autoimmune and infectious diseases, as well as fertility tests. Notable products include IMMUNO-TROL, a quality control tool; various instruments for disease testing; and the SQA-V semen analyzer. TheraDiag also provides advanced instrumentation such as the Theralis platform, which integrates immunofluorescence and ELISA technologies, and the FIDIS platform for laboratory analysis. Additionally, the company offers therapeutic drug monitoring services for chronic inflammatory diseases and LISA tracker, a tool designed for monitoring biotherapies.